Tara Anderson
Family · Houston, TXNPI 1639883853
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,124 of the $2,391 with a category attached, or 88.8%. 16 manufacturers reported payments, led by Gilead at 30.2% of the total. Reporting peaked in 2023 at $1,189 and has fallen 58.0% since, to $500 in 2025.
Across 54 payments — averaging $44.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$722
- AstraZeneca$622
- Lilly USA, LLC$184
- Genentech USA, Inc.$162
- EMD Serono, Inc.$144
- Seagen Inc.$125
- plus $431 from 10 others
What the payments were for
- Food & beverage$2,12489%
- Education$26711%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 15 | $722 |
| AstraZeneca(2 entities) | 16 | $622 |
| Lilly USA, LLC | 2 | $184 |
| Genentech USA, Inc. | 5 | $162 |
| EMD Serono, Inc. | 2 | $144 |
| Seagen Inc. | 1 | $125 |
| Nevro Corp. | 1 | $108 |
| Merck | 3 | $71 |
| Puma Biotechnology, Inc. | 1 | $66 |
| Array Biopharma Inc | 2 | $43 |
| Eisai Inc. | 1 | $34 |
| Novartis | 1 | $33 |
| Taiho Oncology, Inc. | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Caris MPI, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,391 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Exemestane | 12 | $2,714 |
| Letrozole | 38 | $670 |
Paid to pharmacies, not to this prescriber.
Other family in Houston
- Robin BeachHouston$428K
- Sarah AguilarHouston$199K
- Margaret WhiteHouston$85K
- Cheryl HaseebHouston$42K
- Kendrick ClackHouston$28K
- David WeirDallas$959K
- April LopezMcAllen$417K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
- Jill CampbellShenandoah$182K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.